Citius Oncology (CTOR) Non-Current Deferred Tax Liability (2023 - 2026)
Citius Oncology (CTOR) posted quarterly Non-Current Deferred Tax Liability of $2.8 million for Q1 2026, up 24.88% year-over-year from $2.3 million in Q1 2025, and down 7.58% quarter-over-quarter from $3.0 million in Q4 2025.
Citius Oncology (CTOR) Non-Current Deferred Tax Liability (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability rose 24.88% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 24.88% YoY), while the FY2025 annual figure was $2.8 million, up 61.17% from the prior year.
- Non-Current Deferred Tax Liability slipped to $2.8 million in Q1 2026 per CTOR's latest filing, from $3.0 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $3.0 million in Q4 2025 and bottomed at $1.2 million in Q3 2023.
- Historically, Non-Current Deferred Tax Liability has averaged $2.3 million across 4 years, with a median of $2.4 million in 2025.
- Annual changes were most pronounced in 2025 — Non-Current Deferred Tax Liability jumped 61.17% — and 2026, when it increased 24.88%.
- Citius Oncology's Non-Current Deferred Tax Liability stood at $1.2 million in 2023, then surged by 72.94% to $2.0 million in 2024, then surged by 53.05% to $3.0 million in 2025, then retreated by 7.58% to $2.8 million in 2026.
- Business Quant data shows CTOR's Non-Current Deferred Tax Liability at $2.8 million in Q1 2026, $3.0 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Citius Oncology | 80.25 Mn | 80.25 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.82 Mn |
| Mar 31, 2026 | 2.82 Mn |
| Dec 31, 2025 | 3.05 Mn |
| Dec 31, 2025 | 3.05 Mn |
| Sep 30, 2025 | 2.78 Mn |
| Sep 30, 2025 | 2.78 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Mar 31, 2025 | 2.26 Mn |
| Mar 31, 2025 | 2.26 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Sep 30, 2023 | 1.15 Mn |
| Sep 30, 2023 | 1.15 Mn |